[ORAGENICS LOGO]

                                   ORAGENICS

Contact:                                                              For Media:

Paul A. Hassie                                                     Joan Kureczka
Chief Financial Officer                               Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

                       ORAGENICS APPROVED FOR AMEX LISTING

ALACHUA,  FL (May 14, 2004) -  Oragenics,  Inc.  (OTC:  OGEN;  TSX-V:ORA.U),  an
emerging  biotechnology company developing innovative products for human health,
today  announced that its common stock listing  application has been approved by
the American Stock Exchange (the "AMEX").  This approval is contingent  upon the
company being in compliance with all applicable listing standards on the date it
begins  trading on the  Exchange,  and may be rescinded if the Company is not in
compliance  with such  standards.  The  Company's  common  stock is  expected to
commence trading on the AMEX under the trading symbol "ONI" on or around May 20,
2004.

"Listing on the American Stock Exchange  represents a significant  milestone for
us," said Chuck Soponis,  Oragenics  chief executive  officer.  "We believe this
listing will help increase our investor  base, as well as create an  opportunity
for increased liquidity for Oragenics' stockholders."

About the AMEX

The American  Stock  Exchange is the only primary  exchange that offers  trading
across a full range of  equities,  options and  exchange  traded  funds  (ETFs),
including  structured  products  and  HOLDRS(SM).  In  addition to its role as a
national  equities market,  the AMEX is the pioneer of the ETF,  responsible for
bringing the first domestic  product to market in 1993.  Leading the industry in
ETF  listings,  the AMEX lists  more than 120 ETFs.  The AMEX is also one of the
largest options exchanges in the U.S., trading options on broad-based and sector
indexes as well as domestic and foreign  stocks.  For more  information,  please
visit http://www.amex.com.

About Oragenics

Oragenics,  Inc. is an emerging biotechnology company focused on the development
and  licensure of  innovative  products and  technologies  for  improving  human
health.  The company's  lead product is a novel oral rinse for the prevention of
tooth decay,  which is anticipated  to enter clinical  trials in 2004 subject to
FDA  approval.   The  company  is  also  developing  a  novel   antibiotic  with
broad-spectrum  activity against gram-positive  bacteria and a probiotic product
aimed at  maintaining  oral  health.  The company is  headquartered  in Alachua,
Florida.  For more  information  about  Oragenics,  please consult the company's
website at www.oragenics.com.

                                    --More--



Oragenics Approved for AMEX Listing
Page 2 of 2



Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995: This release includes forward-looking  statements which reflect Oragenics'
current  views with respect to future events and  financial  performance.  These
forward-looking statements are based on management's beliefs and assumptions and
information currently available.  The words "believe",  "expect",  "anticipate",
"intend",  "estimate",  "project"  and similar  expressions  which do not relate
solely to historical  matters  identify  forward-looking  statements.  Investors
should be cautious in relying on  forward-looking  statements  because  they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual  results  to  differ   materially   from  those  expressed  in  any  such
forward-looking  statements.  These factors include,  but are not limited to (1)
the  ability to  successfully  complete  development  and  commercialization  of
Oragenics'  Replacement Therapy for prevention of tooth decay, novel antibiotic,
and  probiotic  product for oral health;  (2) the ability to obtain  substantial
additional funding; (3) the ability to develop and commercialize products before
competitors; (4) the ability to develop commercial products with the in-licensed
technology;  (5) our inability to meet all the applicable  Amex initial  listing
requirements and, if listed,  to meet Amex  requirements for continued  listing;
(6) the  actions  of  regulatory  authorities  with  respect  to our  ability to
initiate human trials with any of our products currently under development;  (7)
the inability of any trading to develop on Amex; and (8) other factors  detailed
from time to time in filings with the  Securities  and Exchange  Commission.  We
expressly disclaim any responsibility to update forward-looking  statements. The
TSX Venture Exchange has not reviewed and does not accept responsibility for the
adequacy or accuracy of this news release.

                                      # # #